| 1 |
王 笑，李 鑫，杨学刚，等. 非小细胞肺癌微波消融术后血清Caspase-4变化及意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 218-222.
|
| 2 |
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review[J]. JAMA, 2019, 322(8): 764-774.
|
| 3 |
Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations[J]. Expert Rev Respir Med, 2020, 14(2): 125-136.
|
| 4 |
Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: Current status and future directions[J]. Oncologist, 2019, 24(1): 31-41.
|
| 5 |
Santarpia M, Aguilar A, Chaib I, et al. Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies[J]. Cancers (Basel), 2020, 12(6): 1475-1480.
|
| 6 |
武宜婷，渠景连，郭楠楠，等. 补阳还五汤联合GP化疗方案治疗晚期非小细胞肺癌的临床效果[J]. 中国医药导报，2018, 15(36): 119-122.
|
| 7 |
李小江，张 莹，杨佩颖，等. 消岩汤对肺癌干细胞TGF-β/Smad3/MMP-9信号通路的影响[J]. 中草药，2018, 49(5): 1110-1114.
|
| 8 |
王书航，王 洁. 2018年V3版NCCN非小细胞肺癌指南更新要点解读[J]. 华西医学，2018, 33(4): 388-392.
|
| 9 |
陈文俊. 非小细胞肺癌诊疗指南：循证医学与治疗学基础[M]. 西安市：陕西科学技术出版社，2011: 82-83.
|
| 10 |
李 平. 现代名老中医治疗肺癌经验集[M]. 合肥市：安徽科学技术出版社，2014: 106-107.
|
| 11 |
胡成平，高占成. 肺癌[M]. 北京市：人民卫生出版社，2014: 128-129.
|
| 12 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
|
| 13 |
张瑞婕，戢福云，钱桂生，等. 接触蛋白-1在原发性肺鳞状细胞癌组织中的表达及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 139-143.
|
| 14 |
Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer[J]. Thorac Surg Clin, 2020, 30(2): 215-220.
|
| 15 |
Mazieres J, Kowalski D, Luft A, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(3): 271-280.
|
| 16 |
Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2019, 5(3): 376-383.
|
| 17 |
Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature[J]. Cancer, 2018, 124(2): 271-277.
|
| 18 |
任东峰，孙国芳. 六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效及对患者血管内皮生长因子的影响[J]. 陕西中医，2020, 41(1): 65-67.
|
| 19 |
朱津丽，张 硕，张 莹，等. 消岩汤联合化疗对晚期非小细胞肺癌患者外周血VEGF的影响及其临床疗效[J]. 天津中医药，2020, 37(1): 38-43.
|
| 20 |
熊绍权，罗秋月，李亚玲，等. 大黄芪汤联合化疗抑制晚期非小细胞肺癌新增转移的回顾性临床研究[J]. 成都中医药大学学报，2018, 41(1): 46-49.
|
| 21 |
李小江，邬明歆，孔凡铭，等. 消岩汤联合对症维持治疗晚期非小细胞肺癌的回顾性研究[J]. 中草药，2020, 51(3): 146-150.
|
| 22 |
张蕴超，尹世强，贾英杰，等. 消岩汤治疗甲状腺癌术后患者维持治疗期的临床观察研究[J]. 天津中医药，2019, 36(12): 18-21.
|
| 23 |
张娟莉. 消岩汤联合NP化疗方案治疗晚期肺癌临床疗效及对患者免疫功能的影响[J]. 四川中医，2018, 36(6): 127-129.
|